Global Antidiabetic Glucagon-like Peptide 1 Agonists Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Page: 95

Published Date: 06 Feb 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Related Reports
Product Tags

Description

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

According to our (Global Info Research) latest study, the global Antidiabetic Glucagon-like Peptide 1 Agonists market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Antidiabetic Glucagon-like Peptide 1 Agonists market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Antidiabetic Glucagon-like Peptide 1 Agonists market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2018-2029
Global Antidiabetic Glucagon-like Peptide 1 Agonists market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2018-2029
Global Antidiabetic Glucagon-like Peptide 1 Agonists market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2018-2029
Global Antidiabetic Glucagon-like Peptide 1 Agonists market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Antidiabetic Glucagon-like Peptide 1 Agonists
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Antidiabetic Glucagon-like Peptide 1 Agonists market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, AstraZeneca, Eli Lily, GSK and Sanofi and  etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation
Antidiabetic Glucagon-like Peptide 1 Agonists market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Exenatied
    Liraglutide
    Lixisenatide
    Albiglutide
    Dulaglutide

Market segment by Application
    Hospital
    Pharmacy

Major players covered
    Novo Nordisk
    AstraZeneca
    Eli Lily
    GSK
    Sanofi
    Bristol-Myers Squibb

Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Antidiabetic Glucagon-like Peptide 1 Agonists product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Antidiabetic Glucagon-like Peptide 1 Agonists, with price, sales, revenue and global market share of Antidiabetic Glucagon-like Peptide 1 Agonists from 2018 to 2023.
Chapter 3, the Antidiabetic Glucagon-like Peptide 1 Agonists competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Antidiabetic Glucagon-like Peptide 1 Agonists breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Antidiabetic Glucagon-like Peptide 1 Agonists market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Antidiabetic Glucagon-like Peptide 1 Agonists.
Chapter 14 and 15, to describe Antidiabetic Glucagon-like Peptide 1 Agonists sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Antidiabetic Glucagon-like Peptide 1 Agonists
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Type: 2018 Versus 2022 Versus 2029
        1.3.2 Exenatied
        1.3.3 Liraglutide
        1.3.4 Lixisenatide
        1.3.5 Albiglutide
        1.3.6 Dulaglutide
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Application: 2018 Versus 2022 Versus 2029
        1.4.2 Hospital
        1.4.3 Pharmacy
    1.5 Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size & Forecast
        1.5.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2018 & 2022 & 2029)
        1.5.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity (2018-2029)
        1.5.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price (2018-2029)

2 Manufacturers Profiles
    2.1 Novo Nordisk
        2.1.1 Novo Nordisk Details
        2.1.2 Novo Nordisk Major Business
        2.1.3 Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
        2.1.4 Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.1.5 Novo Nordisk Recent Developments/Updates
    2.2 AstraZeneca
        2.2.1 AstraZeneca Details
        2.2.2 AstraZeneca Major Business
        2.2.3 AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
        2.2.4 AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.2.5 AstraZeneca Recent Developments/Updates
    2.3 Eli Lily
        2.3.1 Eli Lily Details
        2.3.2 Eli Lily Major Business
        2.3.3 Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
        2.3.4 Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.3.5 Eli Lily Recent Developments/Updates
    2.4 GSK
        2.4.1 GSK Details
        2.4.2 GSK Major Business
        2.4.3 GSK Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
        2.4.4 GSK Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.4.5 GSK Recent Developments/Updates
    2.5 Sanofi
        2.5.1 Sanofi Details
        2.5.2 Sanofi Major Business
        2.5.3 Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
        2.5.4 Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.5.5 Sanofi Recent Developments/Updates
    2.6 Bristol-Myers Squibb
        2.6.1 Bristol-Myers Squibb Details
        2.6.2 Bristol-Myers Squibb Major Business
        2.6.3 Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
        2.6.4 Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.6.5 Bristol-Myers Squibb Recent Developments/Updates

3 Competitive Environment: Antidiabetic Glucagon-like Peptide 1 Agonists by Manufacturer
    3.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Manufacturer (2018-2023)
    3.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Manufacturer (2018-2023)
    3.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Manufacturer (2018-2023)
    3.4 Market Share Analysis (2022)
        3.4.1 Producer Shipments of Antidiabetic Glucagon-like Peptide 1 Agonists by Manufacturer Revenue ($MM) and Market Share (%): 2022
        3.4.2 Top 3 Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturer Market Share in 2022
        3.4.2 Top 6 Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturer Market Share in 2022
    3.5 Antidiabetic Glucagon-like Peptide 1 Agonists Market: Overall Company Footprint Analysis
        3.5.1 Antidiabetic Glucagon-like Peptide 1 Agonists Market: Region Footprint
        3.5.2 Antidiabetic Glucagon-like Peptide 1 Agonists Market: Company Product Type Footprint
        3.5.3 Antidiabetic Glucagon-like Peptide 1 Agonists Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Region
        4.1.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Region (2018-2029)
        4.1.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Region (2018-2029)
        4.1.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Region (2018-2029)
    4.2 North America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2018-2029)
    4.3 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2018-2029)
    4.4 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2018-2029)
    4.5 South America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2018-2029)
    4.6 Middle East and Africa Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2018-2029)

5 Market Segment by Type
    5.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2018-2029)
    5.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Type (2018-2029)
    5.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Type (2018-2029)

6 Market Segment by Application
    6.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2018-2029)
    6.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Application (2018-2029)
    6.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Application (2018-2029)

7 North America
    7.1 North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2018-2029)
    7.2 North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2018-2029)
    7.3 North America Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country
        7.3.1 North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2018-2029)
        7.3.2 North America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2018-2029)
        7.3.3 United States Market Size and Forecast (2018-2029)
        7.3.4 Canada Market Size and Forecast (2018-2029)
        7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe
    8.1 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2018-2029)
    8.2 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2018-2029)
    8.3 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country
        8.3.1 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2018-2029)
        8.3.2 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2018-2029)
        8.3.3 Germany Market Size and Forecast (2018-2029)
        8.3.4 France Market Size and Forecast (2018-2029)
        8.3.5 United Kingdom Market Size and Forecast (2018-2029)
        8.3.6 Russia Market Size and Forecast (2018-2029)
        8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific
    9.1 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2018-2029)
    9.2 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2018-2029)
    9.3 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Region
        9.3.1 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Region (2018-2029)
        9.3.2 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Region (2018-2029)
        9.3.3 China Market Size and Forecast (2018-2029)
        9.3.4 Japan Market Size and Forecast (2018-2029)
        9.3.5 Korea Market Size and Forecast (2018-2029)
        9.3.6 India Market Size and Forecast (2018-2029)
        9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
        9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America
    10.1 South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2018-2029)
    10.2 South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2018-2029)
    10.3 South America Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country
        10.3.1 South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2018-2029)
        10.3.2 South America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2018-2029)
        10.3.3 Brazil Market Size and Forecast (2018-2029)
        10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa
    11.1 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2018-2029)
    11.2 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2018-2029)
    11.3 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country
        11.3.1 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2018-2029)
        11.3.2 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2018-2029)
        11.3.3 Turkey Market Size and Forecast (2018-2029)
        11.3.4 Egypt Market Size and Forecast (2018-2029)
        11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
        11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics
    12.1 Antidiabetic Glucagon-like Peptide 1 Agonists Market Drivers
    12.2 Antidiabetic Glucagon-like Peptide 1 Agonists Market Restraints
    12.3 Antidiabetic Glucagon-like Peptide 1 Agonists Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry
    12.5 Influence of COVID-19 and Russia-Ukraine War
        12.5.1 Influence of COVID-19
        12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain
    13.1 Raw Material of Antidiabetic Glucagon-like Peptide 1 Agonists and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Antidiabetic Glucagon-like Peptide 1 Agonists
    13.3 Antidiabetic Glucagon-like Peptide 1 Agonists Production Process
    13.4 Antidiabetic Glucagon-like Peptide 1 Agonists Industrial Chain

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Antidiabetic Glucagon-like Peptide 1 Agonists Typical Distributors
    14.3 Antidiabetic Glucagon-like Peptide 1 Agonists Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 2. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 3. Novo Nordisk Basic Information, Manufacturing Base and Competitors
    Table 4. Novo Nordisk Major Business
    Table 5. Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
    Table 6. Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 7. Novo Nordisk Recent Developments/Updates
    Table 8. AstraZeneca Basic Information, Manufacturing Base and Competitors
    Table 9. AstraZeneca Major Business
    Table 10. AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
    Table 11. AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 12. AstraZeneca Recent Developments/Updates
    Table 13. Eli Lily Basic Information, Manufacturing Base and Competitors
    Table 14. Eli Lily Major Business
    Table 15. Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
    Table 16. Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 17. Eli Lily Recent Developments/Updates
    Table 18. GSK Basic Information, Manufacturing Base and Competitors
    Table 19. GSK Major Business
    Table 20. GSK Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
    Table 21. GSK Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 22. GSK Recent Developments/Updates
    Table 23. Sanofi Basic Information, Manufacturing Base and Competitors
    Table 24. Sanofi Major Business
    Table 25. Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
    Table 26. Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 27. Sanofi Recent Developments/Updates
    Table 28. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
    Table 29. Bristol-Myers Squibb Major Business
    Table 30. Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
    Table 31. Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 32. Bristol-Myers Squibb Recent Developments/Updates
    Table 33. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Manufacturer (2018-2023) & (Units)
    Table 34. Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Manufacturer (2018-2023) & (USD Million)
    Table 35. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Manufacturer (2018-2023) & (US$/Unit)
    Table 36. Market Position of Manufacturers in Antidiabetic Glucagon-like Peptide 1 Agonists, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
    Table 37. Head Office and Antidiabetic Glucagon-like Peptide 1 Agonists Production Site of Key Manufacturer
    Table 38. Antidiabetic Glucagon-like Peptide 1 Agonists Market: Company Product Type Footprint
    Table 39. Antidiabetic Glucagon-like Peptide 1 Agonists Market: Company Product Application Footprint
    Table 40. Antidiabetic Glucagon-like Peptide 1 Agonists New Market Entrants and Barriers to Market Entry
    Table 41. Antidiabetic Glucagon-like Peptide 1 Agonists Mergers, Acquisition, Agreements, and Collaborations
    Table 42. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Region (2018-2023) & (Units)
    Table 43. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Region (2024-2029) & (Units)
    Table 44. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Region (2018-2023) & (USD Million)
    Table 45. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Region (2024-2029) & (USD Million)
    Table 46. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Region (2018-2023) & (US$/Unit)
    Table 47. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Region (2024-2029) & (US$/Unit)
    Table 48. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2018-2023) & (Units)
    Table 49. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2024-2029) & (Units)
    Table 50. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Type (2018-2023) & (USD Million)
    Table 51. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Type (2024-2029) & (USD Million)
    Table 52. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Type (2018-2023) & (US$/Unit)
    Table 53. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Type (2024-2029) & (US$/Unit)
    Table 54. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2018-2023) & (Units)
    Table 55. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2024-2029) & (Units)
    Table 56. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Application (2018-2023) & (USD Million)
    Table 57. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Application (2024-2029) & (USD Million)
    Table 58. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Application (2018-2023) & (US$/Unit)
    Table 59. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Application (2024-2029) & (US$/Unit)
    Table 60. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2018-2023) & (Units)
    Table 61. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2024-2029) & (Units)
    Table 62. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2018-2023) & (Units)
    Table 63. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2024-2029) & (Units)
    Table 64. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2018-2023) & (Units)
    Table 65. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2024-2029) & (Units)
    Table 66. North America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2018-2023) & (USD Million)
    Table 67. North America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2024-2029) & (USD Million)
    Table 68. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2018-2023) & (Units)
    Table 69. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2024-2029) & (Units)
    Table 70. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2018-2023) & (Units)
    Table 71. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2024-2029) & (Units)
    Table 72. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2018-2023) & (Units)
    Table 73. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2024-2029) & (Units)
    Table 74. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2018-2023) & (USD Million)
    Table 75. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2024-2029) & (USD Million)
    Table 76. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2018-2023) & (Units)
    Table 77. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2024-2029) & (Units)
    Table 78. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2018-2023) & (Units)
    Table 79. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2024-2029) & (Units)
    Table 80. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Region (2018-2023) & (Units)
    Table 81. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Region (2024-2029) & (Units)
    Table 82. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Region (2018-2023) & (USD Million)
    Table 83. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Region (2024-2029) & (USD Million)
    Table 84. South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2018-2023) & (Units)
    Table 85. South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2024-2029) & (Units)
    Table 86. South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2018-2023) & (Units)
    Table 87. South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2024-2029) & (Units)
    Table 88. South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2018-2023) & (Units)
    Table 89. South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2024-2029) & (Units)
    Table 90. South America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2018-2023) & (USD Million)
    Table 91. South America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2024-2029) & (USD Million)
    Table 92. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2018-2023) & (Units)
    Table 93. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2024-2029) & (Units)
    Table 94. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2018-2023) & (Units)
    Table 95. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2024-2029) & (Units)
    Table 96. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Region (2018-2023) & (Units)
    Table 97. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Region (2024-2029) & (Units)
    Table 98. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Region (2018-2023) & (USD Million)
    Table 99. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Region (2024-2029) & (USD Million)
    Table 100. Antidiabetic Glucagon-like Peptide 1 Agonists Raw Material
    Table 101. Key Manufacturers of Antidiabetic Glucagon-like Peptide 1 Agonists Raw Materials
    Table 102. Antidiabetic Glucagon-like Peptide 1 Agonists Typical Distributors
    Table 103. Antidiabetic Glucagon-like Peptide 1 Agonists Typical Customers
List of Figures
    Figure 1. Antidiabetic Glucagon-like Peptide 1 Agonists Picture
    Figure 2. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 3. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Type in 2022
    Figure 4. Exenatied Examples
    Figure 5. Liraglutide Examples
    Figure 6. Lixisenatide Examples
    Figure 7. Albiglutide Examples
    Figure 8. Dulaglutide Examples
    Figure 9. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Figure 10. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Application in 2022
    Figure 11. Hospital Examples
    Figure 12. Pharmacy Examples
    Figure 13. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value, (USD Million): 2018 & 2022 & 2029
    Figure 14. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Forecast (2018-2029) & (USD Million)
    Figure 15. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity (2018-2029) & (Units)
    Figure 16. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price (2018-2029) & (US$/Unit)
    Figure 17. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Manufacturer in 2022
    Figure 18. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Manufacturer in 2022
    Figure 19. Producer Shipments of Antidiabetic Glucagon-like Peptide 1 Agonists by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
    Figure 20. Top 3 Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturer (Consumption Value) Market Share in 2022
    Figure 21. Top 6 Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturer (Consumption Value) Market Share in 2022
    Figure 22. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Region (2018-2029)
    Figure 23. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Region (2018-2029)
    Figure 24. North America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2018-2029) & (USD Million)
    Figure 25. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2018-2029) & (USD Million)
    Figure 26. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2018-2029) & (USD Million)
    Figure 27. South America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2018-2029) & (USD Million)
    Figure 28. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2018-2029) & (USD Million)
    Figure 29. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Type (2018-2029)
    Figure 30. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Type (2018-2029)
    Figure 31. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Type (2018-2029) & (US$/Unit)
    Figure 32. Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Application (2018-2029)
    Figure 33. Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Application (2018-2029)
    Figure 34. Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Application (2018-2029) & (US$/Unit)
    Figure 35. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Type (2018-2029)
    Figure 36. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Application (2018-2029)
    Figure 37. North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Country (2018-2029)
    Figure 38. North America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Country (2018-2029)
    Figure 39. United States Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 40. Canada Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 41. Mexico Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 42. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Type (2018-2029)
    Figure 43. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Application (2018-2029)
    Figure 44. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Country (2018-2029)
    Figure 45. Europe Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Country (2018-2029)
    Figure 46. Germany Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 47. France Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 48. United Kingdom Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 49. Russia Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 50. Italy Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 51. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Type (2018-2029)
    Figure 52. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Application (2018-2029)
    Figure 53. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Region (2018-2029)
    Figure 54. Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Region (2018-2029)
    Figure 55. China Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 56. Japan Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 57. Korea Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 58. India Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 59. Southeast Asia Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 60. Australia Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 61. South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Type (2018-2029)
    Figure 62. South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Application (2018-2029)
    Figure 63. South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Country (2018-2029)
    Figure 64. South America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Country (2018-2029)
    Figure 65. Brazil Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 66. Argentina Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 67. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Type (2018-2029)
    Figure 68. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Application (2018-2029)
    Figure 69. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity Market Share by Region (2018-2029)
    Figure 70. Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value Market Share by Region (2018-2029)
    Figure 71. Turkey Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 72. Egypt Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 73. Saudi Arabia Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 74. South Africa Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 75. Antidiabetic Glucagon-like Peptide 1 Agonists Market Drivers
    Figure 76. Antidiabetic Glucagon-like Peptide 1 Agonists Market Restraints
    Figure 77. Antidiabetic Glucagon-like Peptide 1 Agonists Market Trends
    Figure 78. Porters Five Forces Analysis
    Figure 79. Manufacturing Cost Structure Analysis of Antidiabetic Glucagon-like Peptide 1 Agonists in 2022
    Figure 80. Manufacturing Process Analysis of Antidiabetic Glucagon-like Peptide 1 Agonists
    Figure 81. Antidiabetic Glucagon-like Peptide 1 Agonists Industrial Chain
    Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
    Figure 83. Direct Channel Pros & Cons
    Figure 84. Indirect Channel Pros & Cons
    Figure 85. Methodology
    Figure 86. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Related Reports

Global Antidiabetic Glucagon-like Peptide 1 Agonists Supply, Demand and Key Producers, 2023-2029

Global Antidiabetic Glucagon-like Peptide 1 Agonists Supply, Demand and Key Producers, 2023-2029

date 03 Feb 2023

date Pharma & Healthcare

The global Antidiabetic Glucagon-like Peptide 1 Agonists market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Antidiabetic Glucagon-like Peptide 1 Agonists Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Antidiabetic Glucagon-like Peptide 1 Agonists Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 05 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Antidiabetic Glucagon-like Peptide 1 Agonists market size was valued at USD 5543 million in 2023 and is forecast to a readjusted size of USD 7350.8 million by 2030 with a CAGR of 4.1% during review period.

Global Antidiabetic Glucagon-like Peptide 1 Agonists Supply, Demand and Key Producers, 2024-2030

Global Antidiabetic Glucagon-like Peptide 1 Agonists Supply, Demand and Key Producers, 2024-2030

date 24 Feb 2024

date Pharma & Healthcare

The global Antidiabetic Glucagon-like Peptide 1 Agonists market size is expected to reach $ 7350.8 million by 2030, rising at a market growth of 4.1% CAGR during the forecast period (2024-2030).

Product Tags

Antidiabetic Glucagon-like Peptide 1 Agonists

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>